EDITOR IN CHIEF
John Kellett (Denmark)

ASSOCIATE EDITORS
Mikkel Brabrand (Denmark)
Ettore Bartoli (Italy)
Eleni I. Boutati (Greece)
Tim Cooksley (UK)
Dan Justo (Israel)
Radovan Hojs (Slovenia)
Pier Mannuccio Mannucci (Italy)
Alberto M. Marra (Germany)
Carla Araújo Pimentel (Portugal)
Ramon Pujol (Bellvitge, Spain)
Shirley Rigby (UK)
2021... settling after the tsunami

2020 has seen an unprecedent increase in submission, and therefore had the chance to be more selective.
Are COVID-19 articles still relevant for science?

- 18% of 2021 submissions were COVID-19-themed.
- Case reports on this topic, once novel, are now often mere repetition or speculation.
- In 2022 we are accepting even less COVID-19 cases.
Publication data and performance

<table>
<thead>
<tr>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issues</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Articles x issue</td>
<td>8</td>
<td>9-12</td>
<td>&gt; 20</td>
</tr>
<tr>
<td>Submitted</td>
<td>162</td>
<td>343</td>
<td>658</td>
</tr>
<tr>
<td>Accepted</td>
<td>78</td>
<td>162</td>
<td>264</td>
</tr>
<tr>
<td>Published</td>
<td>84</td>
<td>184</td>
<td>292</td>
</tr>
</tbody>
</table>

2021 rejection rate: 63%
Average time to first decision: 6 days
Average time to publication: 40 days

+ 6% 2020

waiting for approval from the author
Looking ahead

2022 data projected as at 31/05/2021

2022 data projected as at 31/05/2021

+ 2% Rej Rate 2021
Credibility vs profitability

• In the last few years we had an increase in submission, which lead to a natural increase of rejections – and work!

• When the number of rejections increases, our credibility increases as well. Most journals boast a high rejection rate, which means that articles are carefully selected for quality reasons.

• However, EJCRIM does funds itself via APCs. To reject more from a bigger pool of manuscripts, it also means to lessen our income, as costs are not sufficiently covered.

• Shall we increase the publication fee to 280/300 euros+ VAT?
A new landscape

Submissions from Extra-European countries have increased as compared to the past years
A new landscape

How’s Europe doing?

PORTUGAL; 54%

NORTH AMERICA 18%

SOUTH AND CENTRAL AMERICA 1%

ASIA 8%

OCEANIA 0%

AFRICA 6%

EUROPE, 60%

ALBANIA; 1%
BELGIUM; 6%
SWITZERLAND; 2%
CYPRUS; 0%
GERMANY; 2%
DENMARK; 0%
SPAIN; 5%
FRANCE; 2%
GREECE; 3%
IRELAND; 1%
ITALY; 13%
MALTA; 1%
NEDERLANDS; 3%
POLAND; 0%

NORTH AMERICA 18%
SOUTH AND CENTRAL AMERICA 1%
ASIA 8%
OCEANIA 0%
AFRICA 6%
EUROPE, 60%
Reader’s favourites in 2021

1. **Hamada et al.** The Very First Change of the Tongue with the Development of Cancer (2017) - 20675 views


3. **Manckoundia et al.** Is Persistent Thick Copious Mucus a Long-Term Symptom of COVID-19? (2020) - 13461 views
### Reader’s favourites in 2021

<table>
<thead>
<tr>
<th>Rank</th>
<th>Author(s)</th>
<th>Title</th>
<th>Views</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td><strong>Dongen et al.</strong></td>
<td>Unusually Rapid Development of Pulmonary Hypertension and Right Ventricular Failure after <strong>COVID-19</strong> Pneumonia (2020)</td>
<td>4709</td>
</tr>
<tr>
<td>5</td>
<td><strong>van Kraaij et al.</strong></td>
<td>Tocilizumab in Severe <strong>COVID-19</strong> Pneumonia and Concomitant Cytokine Release Syndrome (2020)</td>
<td>4560</td>
</tr>
<tr>
<td>6</td>
<td><strong>Amaral et al.</strong></td>
<td><strong>COVID-19</strong> and Cytomegalovirus Co-infection: A Challenging Case of a Critically Ill Patient with Gastrointestinal Symptoms (2020)</td>
<td>4318</td>
</tr>
</tbody>
</table>
Editor’s issues:

• Learning points: why is this “rare” event important?
• Anything with a section/chapter on it in a standard textbook is NOT “rare”
• “To the best of our knowledge” implies an exhaustive search of the literature
• Titles should be written so that a Google search will find them
• Frequent contributors:
  • How many rare conditions does one doctor see in a lifetime?
• Keep it simple and short, and relevant to Internal Medicine
**Web Traffic**

- **Monthly visitors:** About 5,600
- **Pages consulted during each visit:** 2.5
- **Total sessions:** 91,886

**Most traffic comes from:**

- **Organic search (keywords):** 55%
- **Direct search (web address):** 30%
- **Referrals (external sites):** 11%
- **Social Media:** 4%

**Traffic from channels:** +600/month

**Originating countries:**
1. **United States**
2. **India**
3. **United Kingdom**
4. **China**
5. **Portugal**
6. **Indonesia**
7. **Italy**
8. **Japan**
9. **Canada**
10. **Germany**

**Graph:**
- **Utenti**
- **Dates:** Feb 2021 to Dec 2021
Social Media

About 5% of the sessions originate from Social Media of different kinds.

- Our Facebook is our community of 3300 internists from all over the world. www.facebook.com/ejcrim
- A growing community. It’s time to follow us and join the conversation. www.twitter.com/ejcrim
- Many authors love to share their academic achievements on Linkedin.
- YouTube is mostly used to host our author’s video material www.youtube.com/ejcrim
Who links our content...

About 11% of the sessions originate from referrals: external sites that have our link and in some cases co-host our content.

- PubMed: 10%
- PubMed Central: 5%
- Sci-Hub: 11.5%
- Google Scholar: 6%
- DOAJ: 3%
Citations of articles published in 2020-2021

1827 total citations*

*Citations are counted from Google Scholar
What are we doing in 2022?

- **Abstract Book** of the 20th ECIM Conference
- **Media Kit** to attract sponsors for our initiatives
- Welcoming sponsored supplements
- A collaboration with **EFIM academy**
Let’s write a new future for the Journal

EJCRIM is not a «small journal» anymore. Welcoming new features for further development:

• A collaboration with EFIM Academy… our authors could be selected for a talk for the Home of Medicine Podcast
• Themed Collections
• Webinars and educational programmes
• Hospital Grand Rounds, with new hospitals
Let’s write a new future for the Journal

Application for Scopus

Implementation of RightsLink

Getting ready for PLAN S
Get in touch with us if you wish to collaborate and/or share ideas!

info@ejcrim.com